Shark vs. Pharma: Can Cuban’s Cost Plus Drugs Make a Real Impact on Medication Prices?
There’s a lot of frustration about drug pricing in America right now. Across the country, many voices have joined RxBenefits...
Mark Campbell, PharmD's Posts
Biosimilars, GLP-1s, and Stop-loss: Topics Benefit Advisors Need to Consider in Q3 2023
Making the best recommendation to your clients requires looking beyond the spreadsheet comparisons of price points and building a layered...
Caring For Members Doesn’t Have to Lead to Wasted Pharmacy Spend
The pharmacy industry can feel confusing, cold, and conflicting for plan sponsors and members. Benefits advisor often see the complicated...
What Employers Need to Know About Drug Rebates
Prescription drug rebates have been around for a long time. They are a central piece in the overall economic...
How Clinical Rx Management Protects Members & Plan Sponsors
When someone is using a specialty medication, the inclination is to think that they have a severe condition, they are...
Improving the Clinical & Economic Value of Pharmacy Benefit Plan Strategies
Top 3 Things You’ll Learn 5 ways to improve pharmacy benefit clinical and economic value for 2021 How to balance...
What to Expect When You Contract With a PBO
The prescription benefits landscape has changed a lot over the last 20 years. Today, the three largest pharmacy benefits management...
Prescription Drug Utilization Trends: COVID-19 & Beyond
In any given year, following prescription drug utilization trends always has its challenges. It’s been especially interesting looking back on...
Three Things to Know About Specialty Drug Costs & Utilization
There are a lot of essential and very expensive specialty medications on the market. If someone is taking a specialty...
